Active ingredient:( Imipenem 500mg/cilastatin 500mg)

– Antibiotic Infusion

– Carpabenem (B-Lactam group)

learn more about Ayapenam Trials… click here


Mechanism of action:

  • Bactericidal effect cause rapid bacterial cell death by covalently binding to penicillin-binding proteins (PBPs) involved in the biosynthesis of mucopeptides in bacterial cell walls.
  • Bactericidal effects result through inhibition of cellular growth and division and the loss of cell wall integrity,eventually causing cell wall lysis.

Indication of Ayapenam:

  • Lower respiratory tract infections
  • Urinary tract infections.
  • Intra-abdominal infections.
  • Gynaecologic infections.
  • Bacterial septicaemia.
  • Bone and joint infections.
  • Skin and skin structure infections.
  • Endocarditis.
  • Prevention of post-operative infection.

Imipenem vs Meropenem:

  • 1.5 g/day of imipenem/cilastatin is shown to be effective to 3g/day meropenem in clinical and bacteriological outcome, as well as in incidence of side effects.
  • Treatment of intra-abdominal infections with imipenem/cilastatin is shown to be more effective & less costy than meropenem.
  • Incidence of meropenem resistance higher than that of imipenem/cilastatin across clinically significant nosocomial pathogen.
  • Over all imipenem/cilastatin showed better activity than meropenem in pseudomonas spp, acinetobacter spp, e-coli& klebsiella spp.
  • Imipenem/cilastatin is the antibiotic of choice for preventing infections of pancreatic necrosis.